Prognostic value of oxygen saturation and heart rate during a six-minute walk test in pediatric pulmonary hypertension

Oguz, Ayse Deniz; CANBEYLİ, Fatma; Tunaoğlu, Fatma Sedef; KULA, Serdar; ATASAYAN, VİLDAN; Çelik, Bülent

doi:10.3906/sag-2004-220

Prognostic value of oxygen saturation and heart rate during a six-minute walk test in pediatric pulmonary hypertension

Vildan ATASAYAN, (Ümraniye Eğitim ve Araştırma Hastanesi, Çocuk Kardiyolojisi Anabilim Dalı, İstanbul, Türkiye)

Fatma CANBEYLİ, (Kırıkkale Üniversitesi, Tıp Fakültesi, Çocuk Kardiyolojisi Anabilim Dalı, Kırıkkale, Türkiye)

Fatma Sedef TUNAOGLU, (Gazi Üniversitesi, Tıp Fakültesi, Çocuk Kardiyolojisi Anabilim Dalı, Ankara, Türkiye)

Ayse Deniz OĞUZ, (Gazi Üniversitesi, Tıp Fakültesi, Çocuk Kardiyolojisi Anabilim Dalı, Ankara, Türkiye)

Bülent ÇELİK, (Gazi Üniversitesi, Fen Fakültesi, İstatistik Bölümü, Ankara, Türkiye)

Serdar KULA (Ümraniye Eğitim ve Araştırma Hastanesi, Çocuk Kardiyolojisi Anabilim Dalı, İstanbul, Türkiye)

Turkish Journal of Medical Sciences

0 0

Yıl: 2021 Cilt: 51 Sayı: 4 Sayfa Aralığı: 1833 - 1840 Metin Dili: İngilizce DOI: 10.3906/sag-2004-220 İndeks Tarihi: 12-01-2022

Prognostic value of oxygen saturation and heart rate during a six-minute walk test in pediatric pulmonary hypertension

Öz:

Background/aim: To evaluate the pre and post-treatment heart rate and oxygen (O2 ) saturation values measured before, during and after 6MWT in children who received PAH-specific treatment and to determine the effect of these variables on prognosis. Materials and methods: This retrospective study included 29 patients who were diagnosed as PAH and treated. The transcutaneous O2 saturationand heart rate levels were recorded before the test: baseline (Sat0, HR0), at the end of the test: exercise (Sat1,HR1) and 5 min after the test: recovery (Sat2, HR2). The increase in heart rate was defined as HR1-HR0 and the decrease in saturation as Sat0-Sat1. The results obtained before and after the PAH-specific treatment were analyzed and their effect on survival was assessed. Results: Fifteen of 29 patients were female (51.7%). The mean age was 127.2 ± 44.8 months and the median follow-up time was 60 (12–156) months. Only pre-treatment HR1 was found associated with survival. The mean HR1 value of survivors was 122.8 ± 18.4 and that of deceased 94.3 ± 19.1 (p = 0.03). Post-treatment 6MWT was associated with survival. It was 453.3 ± 96.5 m for survivors and 250 ± 135.2 m for deceased (p = 0.02). Conclusion: Post-treatment 6MWT, FC and proBNP had prognostic value in pediatric patients with PAH. The decrease in saturation and increase in heart rate were not found to have a prognostic value. Pre-treatment HR1 was associated with survival. Identification of these prognostic factors at the beginning and throughout the treatment may be a guide for detecting the severity of the disease and follow-up.Key words: 6-minute walk test, pulmonary arterial hypertension, survival, heart rate

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). European Respiratory Journal 2015; 46: 903-975. doi: 10.1093/eurheartj/ehv317
2. Abman SH, Hansmann G, Archer SL, Ivy DD, Adatia I et al. Pediatric pulmonary hypertension: guidelines from the American Heart Association and American Thoracic Society. Circulation 2015; 132: 2037-2099. doi: 10.1161/ CIR.0000000000000329
3. Hansmann G, Apitz C, Abdul- Khaliq H, Alastalo TP, Beerbaum P et al. Executive summary. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The european paediatric pulmonary vascular disease network, endorsed by ISHLT and DGPK. Heart 2016; 102 (2): 86-100. doi: 10.1136/heartjnl-2015-309132
4. Kula S, Pektaş A. A review of pediatric pulmonary hypertension with new guidelines. Turkish Journal of Medical Sciences 2017; 47 (2): 375-380. doi: 10.3906/sag-1605-172
5. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ et al. Predicting survival in pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management (REVEAL). Circulation 2010; 122: 164-172. doi: 10.1161/CIRCULATIONAHA.109.898122
6. Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. American Journal of Respiratory and Critical Care Medicine 2000; 161: 487-492. doi: 10.1164/ajrccm.161.2.9906015
7. Ivy DD, Abman SH, Barst RJ, Berger RMF, Bonnet D et al. Pediatric pulmonary hypertension. Journal of American College of Cardiology 2013; 62 (25): 117-126. doi: 10.1016/j. jacc.2013.10.028
8. Moledina S, Pandya B, Bartsota M, Mortensen KH, McMillan M et al. Prognostic significance of cardiac magnetic resonance imaging in children with pulmonary hypertension. Circulation Cardiovascular Imaging 2013; 6 (3): 407-414. doi: 10.1161/ CIRCIMAGING.112.000082
9. Wagner BD, Takatsuki S, Accurso FJ, Ivy DD. Evaluation of circulating proteins and hemodynamics towards predicting mortality in children with pulmonary arterial hypertension. PLoS One 2013; 8 (11): 80235. doi: 10.1371/journal. pone.0080235
10. Lammers AE, Munnery E, Hislop AA, Haworth SG. Heart rate variability predicts outcome in children with pulmonary arterial hypertension. International Journal of Cardiology 2010; 142 (2): 159-165. doi: 10.1016/j.ijcard.2008.12.087
11. Barst RJ, McGoon MD, Elliott CG, Foreman AJ, Miller DP et al. Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Circulation 2012; 125: 113-122. doi: 10.1161/CIRCULATIONAHA.111.026591
12. Moledina S, Hislop AA, Foster H, Schulze-Neick I, Haworth SG. Childhood idiopathic pulmonary arterial hypertension: a national cohort study. Heart 2010; 96: 1401-1406. doi: 10.1136/ hrt.2009.182378
13. Ramos RP, Arakaki JS, Barbosa P, Treptow E, Valois FM et al. Heart rate recovery in pulmonary arterial hypertension: relationship with exercise capacity and prognosis. American Heart Journal 2012; 163: 580-588. doi: 10.1016/j. ahj.2012.01.023
14. Paciocco G, Martinez FJ, Bossone E, Pielsticker E, Gillespie B et al. Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. European Respiratory Journal 2001; 17: 647-652. doi: 10.1183/09031936.01.17406470
15. Minai OA, Gudavalli R, Mummadi S, Liu X, McCarthy K et al. Heart rate recovery predicts clinical worsening in patients with pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine 2012; 185: 400-408. doi: 10.1164/rccm.201105-0848OC
16. Douwes JM, Hegemanb AK, Van der Krieke MB, Roofthooft MTR, Hillege HL et al. Six-minute walking distance and decrease in oxygen saturation during the six-minute walk test in pediatric pulmonary arterial hypertension. International Journal of Cardiology 2016; 202: 34-39. doi: 10.1016/j. ijcard.2015.08.155
17. Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D et al. Definitions and diagnosis of pulmonary hypertension. Journal of American College of Cardiology 2013; 62 (25): 42- 50. doi: 10.1016/j.jacc.2013.10.032
18. ATS committee on proficiency standards for clinical pulmonary function laboratories. ATS statement: guidelines for the six-minute walk test. American Journal of Respiratory and Critical Care Medicine 2002; 166: 111-117. doi: 10.1164/ ajrccm.166.1.at1102
19. Zuk M, Migdal A, Jagiellowicz-Kowalska D, Mazurkiewicz K, Sadel-Wieczorek A et al. Six-minute walk test in evaluation of children with pulmonary arterial hypertension. Pediatric Cardiology 2017; 38: 754-761. doi: 10.1007/s00246-017-1575-z
20. Van Loon RL, Roofthooft MT, Delhaas T, Van Osch-Gevers M, Ten Harkel AD et al. Outcome of pediatric patients with pulmonary arterial hypertension in the era of new medical therapies. American Journal of Cardiology 2010; 106: 117-124. doi: 10.1016/j.amjcard.2010.02.023
21. Ploegstra MJ, Douwes JM, Roofthooft MT, Zijlstra WM, Hillege HL et al. Identification of treatment goals in paediatric pulmonary arterial hypertension. European Respiratory Journal 2014; 44: 1616-1626. doi: 10.1183/09031936.00030414
22. Lammers AE, Diller GP, Odendaal D, Tailor S, Derrick G et al. Comparison of 6-min walk test distance and cardiopulmonary exercise test performance in children with pulmonary hypertension. Archives of Disease in Childhood 2011; 96: 141- 147. doi: 10.1136/adc.2009.169904
23. Paolillo S, Farina S, Bussotti M, Iorio A, PerroneFilardi P et al. Exercise testing in the clinical management of patients affected by pulmonary arterial hypertension. European Journal of Preventive Cardiology 2012; 19: 960-971. doi: 10.1177/1741826711426635
24. Ploegstra MJ, Zijlstra WM, Douwes JM, Hillege HL, Berger RM. Prognostic factors in pediatric pulmonary arterial hypertension: a systematic review and meta-analysis. International Journal of Cardiology 2015; 184: 198-207. doi: 10.1016/j.ijcard.2015.01.038
25. Galiè N, Rubin Lj, Hoeper M, Jansa P, Al-Hiti H et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a doubleblind, randomised controlled trial. Lancet 2008; 371 (9630): 2093-2100. doi: 10.1016/S0140-6736(08)60919-8
26. Fraisse A, Jais X, Schleich JM, Filippo SD, Maragnès P et al. Characteristics and prospective 2-year follow-up of children with pulmonary arterial hypertension in France. Archives of Cardiovascular Diseases 2010; 103 (2): 66-74. doi: 10.1016/j. acvd.2009.12.001
27. Hislop AA, Moledina S, Foster H, Schulze-Neick I, Haworth SG. Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children. European Respiratory Journal 2011; 38 (1): 70-77. doi: 10.1183/09031936.00053510

APA	ATASAYAN V, CANBEYLİ F, Tunaoğlu F, Oguz A, Çelik B, KULA S (2021). Prognostic value of oxygen saturation and heart rate during a six-minute walk test in pediatric pulmonary hypertension. , 1833 - 1840. 10.3906/sag-2004-220
Chicago	ATASAYAN VİLDAN,CANBEYLİ Fatma,Tunaoğlu Fatma Sedef,Oguz Ayse Deniz,Çelik Bülent,KULA Serdar Prognostic value of oxygen saturation and heart rate during a six-minute walk test in pediatric pulmonary hypertension. (2021): 1833 - 1840. 10.3906/sag-2004-220
MLA	ATASAYAN VİLDAN,CANBEYLİ Fatma,Tunaoğlu Fatma Sedef,Oguz Ayse Deniz,Çelik Bülent,KULA Serdar Prognostic value of oxygen saturation and heart rate during a six-minute walk test in pediatric pulmonary hypertension. , 2021, ss.1833 - 1840. 10.3906/sag-2004-220
AMA	ATASAYAN V,CANBEYLİ F,Tunaoğlu F,Oguz A,Çelik B,KULA S Prognostic value of oxygen saturation and heart rate during a six-minute walk test in pediatric pulmonary hypertension. . 2021; 1833 - 1840. 10.3906/sag-2004-220
Vancouver	ATASAYAN V,CANBEYLİ F,Tunaoğlu F,Oguz A,Çelik B,KULA S Prognostic value of oxygen saturation and heart rate during a six-minute walk test in pediatric pulmonary hypertension. . 2021; 1833 - 1840. 10.3906/sag-2004-220
IEEE	ATASAYAN V,CANBEYLİ F,Tunaoğlu F,Oguz A,Çelik B,KULA S "Prognostic value of oxygen saturation and heart rate during a six-minute walk test in pediatric pulmonary hypertension." , ss.1833 - 1840, 2021. 10.3906/sag-2004-220
ISNAD	ATASAYAN, VİLDAN vd. "Prognostic value of oxygen saturation and heart rate during a six-minute walk test in pediatric pulmonary hypertension". (2021), 1833-1840. https://doi.org/10.3906/sag-2004-220

APA	ATASAYAN V, CANBEYLİ F, Tunaoğlu F, Oguz A, Çelik B, KULA S (2021). Prognostic value of oxygen saturation and heart rate during a six-minute walk test in pediatric pulmonary hypertension. Turkish Journal of Medical Sciences, 51(4), 1833 - 1840. 10.3906/sag-2004-220
Chicago	ATASAYAN VİLDAN,CANBEYLİ Fatma,Tunaoğlu Fatma Sedef,Oguz Ayse Deniz,Çelik Bülent,KULA Serdar Prognostic value of oxygen saturation and heart rate during a six-minute walk test in pediatric pulmonary hypertension. Turkish Journal of Medical Sciences 51, no.4 (2021): 1833 - 1840. 10.3906/sag-2004-220
MLA	ATASAYAN VİLDAN,CANBEYLİ Fatma,Tunaoğlu Fatma Sedef,Oguz Ayse Deniz,Çelik Bülent,KULA Serdar Prognostic value of oxygen saturation and heart rate during a six-minute walk test in pediatric pulmonary hypertension. Turkish Journal of Medical Sciences, vol.51, no.4, 2021, ss.1833 - 1840. 10.3906/sag-2004-220
AMA	ATASAYAN V,CANBEYLİ F,Tunaoğlu F,Oguz A,Çelik B,KULA S Prognostic value of oxygen saturation and heart rate during a six-minute walk test in pediatric pulmonary hypertension. Turkish Journal of Medical Sciences. 2021; 51(4): 1833 - 1840. 10.3906/sag-2004-220
Vancouver	ATASAYAN V,CANBEYLİ F,Tunaoğlu F,Oguz A,Çelik B,KULA S Prognostic value of oxygen saturation and heart rate during a six-minute walk test in pediatric pulmonary hypertension. Turkish Journal of Medical Sciences. 2021; 51(4): 1833 - 1840. 10.3906/sag-2004-220
IEEE	ATASAYAN V,CANBEYLİ F,Tunaoğlu F,Oguz A,Çelik B,KULA S "Prognostic value of oxygen saturation and heart rate during a six-minute walk test in pediatric pulmonary hypertension." Turkish Journal of Medical Sciences, 51, ss.1833 - 1840, 2021. 10.3906/sag-2004-220
ISNAD	ATASAYAN, VİLDAN vd. "Prognostic value of oxygen saturation and heart rate during a six-minute walk test in pediatric pulmonary hypertension". Turkish Journal of Medical Sciences 51/4 (2021), 1833-1840. https://doi.org/10.3906/sag-2004-220